Biotech vets jump on board a start­up, raise cash and take aim at the clin­ic with an­ti-in­flam­ma­to­ry drugs

A Salt Lake City-based biotech start­up is jump­ing on board the an­ti­body train — and it’s equip­ping it­self for the jour­ney ahead with a round of VC fi­nanc­ing.

Sor­riso Phar­ma­ceu­ti­cals an­nounced this morn­ing that it closed a Se­ries A worth $31 mil­lion in a round co-led by Ar­ix Bio­science and New En­ter­prise As­so­ciates. Sor­riso’s new fund­ing will ad­vance the biotech’s oral an­ti­body pipeline — specif­i­cal­ly its lead can­di­date through pre­clin­i­cal de­vel­op­ment, ac­cord­ing to a Sor­riso state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER